---
layout: default
title: Venetoclax
parent: 僅模型預測 (L5)
nav_order: 719
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Venetoclax: From Chronic Lymphocytic Leukaemia (Established Use) to CLL/SLL with IGHV Somatic Hypermutation

## One-Sentence Summary

Venetoclax is a BCL-2 inhibitor already established in the treatment of B-cell haematological malignancies, most notably chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML).
The TxGNN model's top-ranked prediction for this drug is **CLL/SLL with immunoglobulin heavy chain variable-region gene somatic hypermutation** — essentially a molecularly-defined subtype of a disease venetoclax is already widely used for.
This specific top-ranked prediction currently has **no clinical trials and no literature captured in the evidence pack**, and key regulatory data (TGA warnings, contraindications, Australian market status) is missing, so this candidate should be treated as unconfirmed pending data remediation.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (regulatory/MOA data gap — see Data Gaps below). Venetoclax is publicly known as a BCL-2 inhibitor used in CLL and AML; this has not been independently confirmed by the pack's own source data. |
| Predicted New Indication | Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with IGHV somatic hypermutation |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature attached to this specific ranked entry) |
| Australia Market Status | Not marketed (per evidence pack; likely a data-collection gap — see note under Australia Market Information) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for venetoclax is not available in this evidence pack (Data Gap DG002, High severity). Based on the literature captured elsewhere in this evidence pack (e.g. PMID 28724540, PMID 35659041), venetoclax is a selective, oral BH3-mimetic that inhibits BCL-2, restoring apoptosis in malignant B cells that are dependent on BCL-2 overexpression for survival. This mechanism is well characterised in CLL, where venetoclax (alone or with rituximab/obinutuzumab) is an established standard of care.

The predicted indication here — CLL/SLL with IGHV somatic hypermutation — is a **molecularly-defined subtype of CLL/SLL rather than a distinct disease**. A near-identical TxGNN score (99.55%) was also assigned to "pregerminal center CLL/SLL" (rank 2), and closely related entries such as follicular lymphoma, Hodgkin/non-Hodgkin lymphoma spectrum disease, and AML (ranks 3–8) carry extensive supporting clinical trial and literature evidence within the same evidence pack. This pattern is consistent with the model recognising venetoclax's genuine, already-substantiated efficacy across BCL-2-dependent B-cell and myeloid malignancies, rather than identifying a genuinely novel therapeutic area. In other words, this specific ranked prediction likely reflects a refinement of known activity rather than true repurposing — a nuance worth flagging before treating it as a novel signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

*Note: The immediately adjacent prediction (rank 2, "pregerminal center CLL/SLL", identical 99.55% score) and several other closely related TxGNN predictions for this drug (follicular lymphoma, Hodgkin/non-Hodgkin lymphoma spectrum, myeloid leukaemia, CML) are supported by dozens of registered trials, including completed Phase 3 studies (e.g. NCT02950051, NCT03112174, NCT03984448). These are not specific to the IGHV-mutated CLL/SLL subtype named in this top-ranked entry and are not tabulated here per the evidence pack's scope, but they support the drug's broader biological plausibility.*

---

## Literature Evidence

Currently no related literature available.

*Note: The closely related rank-2 prediction is supported by one publication ([PMID 35158929](https://pubmed.ncbi.nlm.nih.gov/35158929/), 2022, review) discussing tumour B-cell receptor structure in IGHV-mutated vs unmutated CLL, which is directly relevant background for this rank-1 prediction's disease biology even though it was not indexed against this exact entry.*

---

## Australia Market Information

No ARTG entries were returned in this evidence pack. The `taiwan_regulatory` record for venetoclax states market status as **"未上市" (Not marketed)** with 0 registered licenses.

⚠️ This is flagged as a likely data-collection gap rather than a confirmed market-absence, given venetoclax's status as a globally established oncology therapy. Direct verification against the TGA/ARTG database is recommended before this is relied upon for any regulatory decision.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BCL-2 inhibitor / BH3-mimetic) |
| Myelosuppression Risk | High — per evidence pack literature (PMID 35659041): "tumour lysis syndrome and myelosuppression are the most commonly encountered" toxicities with venetoclax in lymphoid malignancies |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions — not characterised in this evidence pack |
| Monitoring Items | Full blood count (with differential); tumour lysis syndrome monitoring (electrolytes, renal function, uric acid), particularly during dose ramp-up |
| Handling Protection | Oral antineoplastic agent — cytotoxic drug handling precautions apply per local institutional policy |

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack's own safety fields (key warnings, contraindications, drug–drug interactions) are currently unpopulated (Data Gap DG001, **Blocking severity** — prevents entry into S1 safety initial assessment).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (CLL/SLL with IGHV somatic hypermutation) has zero clinical trial or literature evidence attached in this evidence pack (Evidence Level L5), and a Blocking-severity data gap (missing TFDA/TGA warnings and contraindications) prevents progression to initial safety assessment (S1). This prediction also appears to reflect a molecular refinement of venetoclax's already-established activity in CLL rather than a genuinely novel repurposing signal.

**To proceed, the following is needed:**
- TGA-approved Product Information (warnings, contraindications, drug interactions) for venetoclax
- Confirmation of Australian ARTG/market registration status, which appears inconsistent with venetoclax's known global approval status
- Mechanism of action detail via DrugBank API (Data Gap DG002)
- If this specific molecular-subtype prediction is to be pursued, a targeted literature/trial search for "IGHV-mutated CLL/SLL + venetoclax" to substantiate evidence beyond L5
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

